Efficacy of Eribulin in Soft Tissue Sarcomas

Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated advanced Liposarcoma and Leiomyosarcoma demonstrated superiority of eribulin to...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Edward Phillips, Robin L. Jones, Paul Huang, Antonia Digklia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-03-01
Subjects:	sarcoma eribulin and related compounds eribulin STS liposarcoma leiomyosarcoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.869754/full

Similar Items

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
by: Jonathan Noujaim, et al.
Published: (2016-01-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Recent Advances in the Treatment of Metastatic Soft Tissue Sarcoma
by: Elizabeth J. Davis, et al.
Published: (2018-12-01)

Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01)

Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells
by: Mana Azumi, et al.
Published: (2022-12-01)

Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
by: Motoki Matsuura, et al.
Published: (2023-06-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
by: Soumita Poddar, et al.
Published: (2023-08-01)

Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
by: L. A. Tashireva, et al.
Published: (2022-01-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
by: E. I. Kovalenko, et al.
Published: (2021-12-01)

Eribulin in Heavily Pre-Treated Metastatic Breast Cancer: A Case Series
by: Andini Kartikasari, et al.
Published: (2025-04-01)

Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma
by: Tanner Mack, et al.
Published: (2022-09-01)

CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS
by: P. V. Мazin, et al.
Published: (2017-05-01)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
by: Tetsu Hayashida, et al.
Published: (2018-06-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
by: Mengqian Ni, et al.
Published: (2024-09-01)

Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
by: Herleeyana Meriyani, et al.
Published: (2025-02-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice
by: I. V. Kolyadina
Published: (2021-10-01)

Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
by: Mengya Feng, et al.
Published: (2024-12-01)

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
by: Lan Chen, et al.
Published: (2024-05-01)

Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
by: A. V. Sultanbaev, et al.
Published: (2023-04-01)

Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
by: Meng-Xia Su, et al.
Published: (2024-02-01)

Eribulin mesylate exerts antitumor effects via CD103
by: Kazumasa Oya, et al.
Published: (2023-12-01)

Prognostic significance of neutrophil to lymphocyte ratio in patients with metastatic breast cancer on the background of eribulin therapy
by: A. V. Zyuzyukina, et al.
Published: (2022-09-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study
by: Yuting Li, et al.
Published: (2025-06-01)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
by: Takahiro Ishizaka, et al.
Published: (2023-06-01)

Surgical Management of Retroperitoneal Sarcoma
by: Dana A. Dominguez, et al.
Published: (2023-04-01)

Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
by: Xinyu Gui, et al.
Published: (2023-08-01)

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
by: Bahram Sharif-Askari, et al.
Published: (2023-03-01)

Retroperitoneal Sarcomas: An Update on the Diagnostic Pathology Approach
by: Joon Hyuk Choi, et al.
Published: (2020-08-01)

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study
by: Kristina Fanucci, et al.
Published: (2025-09-01)

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells
by: Matteo Giulietti, et al.
Published: (2024-03-01)

Long-term survival with eribulin monotherapy after whole brain radiation therapy in a patient with brain metastasis from breast cancer
by: Sung Ui Jung, et al.
Published: (2020-10-01)

Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides
by: Søren Brøgger Christensen
Published: (2022-09-01)

Primary Sarcomas of the Larynx: A Case Series of Four Different Histopathologic Types
by: Ala S. Abu-Dayeh, et al.
Published: (2023-10-01)